A proof-of-concept feasibility is established for EV-mediated delivery of Bace1-targeting siRNA to the brain and further development of engineered EVs as a therapeutic platform for neurodegenerative diseases is supported.
AppSAA mice recapitulate age-dependent, human-relevant AD phenotypes with defined therapeutic windows for preclinical research and is available without restriction from The Jackson Laboratory.
Lucy J. Sloan, Dylan T. Garceau, Nick J. Ryan et al.· bioRxiv· 0 citations
Alzheimer’s disease (AD) is an unremitting neurodegenerative disorder characterized by the presence of extracellular β-amyloid (Aβ)-containing neuritic plaques, intracellular tau-positive neurofibrillary tangles and loss of selected neurons in the brain. Evidence suggests that aggregation of Aβ and tau via synergistic...
P. Paul, Aliza Borenstein-Katz, Klinton Shmeit et al.· International Journal of Mol...· 0 citations
HAMSC-EVs exert robust anti-inflammatory and neuroprotective effects in both murine and human AD models, improving cognition, modulating glial activation, and restoring synaptic integrity, and highlight the translational potential of intranasal hAMSC-EVs as an adjuvant therapeutic strategy targeting neuro inflammation...
Andrea Papait, F. Natale, A. Silini et al.· Translational Neurodegenerat...· 0 citations
Extracellular amyloid plaques from Aβ accumulation and intracellular neurofibrillary tangles (NFTs) from hyperphosphorylated Tau (p-Tau), both leading to neuronal dysfunction, synapse loss, and cognitive decline. Nonetheless, achieving an effective therapeutic outcome is challenging due to the limited drug bioavailabil...
The rational design of H102-CP05, a 22-residue chimeric peptide that integrates the β-sheet breaker peptide H102 with the CD63-targeting anchor CP05 to enable extracellular vesicle (EV) delivery of an Aβ-inhibitory payload is reported, supporting H102-CP05 as a promising EV-displayed therapeutic candidate for AD.
V. Singh, Raja Natesan Sella· Journal of drug targeting (P...· 0 citations
E engineered exosomes are highlighted as efficient nanoplatforms for precision therapy in neurodegenerative diseases by reducing β-amyloid deposition, suppressing neuroinflammation, and repairing neuronal damage in AD.
Chun-Bin Sun, S. Sha, Jian Kang et al.· Nanomedicine: Nanotechnology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.